TMSP(SH:600671)2024-06-04 14:12Financial Correction Impact - The correction will reduce the company's operating revenue by CNY 10.5962 million and operating costs by the same amount for Q1 2024[1]. - The total operating revenue after correction for Q1 2024 is CNY 27,735,233.63, compared to CNY 38,331,441.82 before correction[7]. - The total operating costs after correction for Q1 2024 is CNY 38,900,790.52, compared to CNY 49,496,998.71 before correction[7]. - The adjusted operating revenue growth rate for Q1 2024 is 24.64%, down from 72.25% before correction[8]. Revenue Sources - The increase in revenue is primarily due to a CNY 3.76 million increase from the subsidiary Hangzhou Sanshen Tai Traditional Chinese Medicine Clinic and a CNY 2.25 million increase from Shanghai Tianmu Mountain Pharmaceutical Technology Co., Ltd.[8]. Assurance and Approval - The company confirmed that the correction will not affect total assets, net assets, or total profit for the year 2023[4]. - The audit committee and supervisory board approved the correction, stating it reflects the company's actual operating conditions[10][11]. Revenue Recognition and Management - The company will adopt a net method for revenue recognition for the business with Dongfang Guoyao, reflecting a cautious approach[4]. - The financial data correction aims to enhance the quality of financial information disclosed by the company[10]. - The company emphasizes the importance of strengthening financial management to prevent similar issues in the future[10].